|
124 Companies |
|
161 Products |
|
161 Products |
|
116 Mechanisms of Action |
|
11 Trials |
|
2428 News |
|
| «12...3233343536373839404142...4950» |
- efavirenz / Generic mfg., lopinavir/ritonavir / Generic mfg.
Enrollment change: LIPOKAL: Clinical Trial to Assess the Effect of the Change of Efavirenz (EFV) for Lopinavir/Ritonavir (LPV/r) in Lipoatrophy in HIV-infected Patients (clinicaltrials.gov) - Feb 20, 2013
P4, N=20, Active, not recruiting, Sponsor: Juan A. Arnaiz
N=60 --> 20
- escitalopram / Generic mfg.
New P4 trial: A Trial Examining the Efficacy of Escitalopram Oxalate Upon Depressive Symptoms and Fatigue in HIV Seropositive Women (clinicaltrials.gov) - Feb 20, 2013
P4, N=5, Terminated, Sponsor: Duke University
- Selzentry (maraviroc) / ViiV Healthcare
Enrollment open: Study Comparing Two Alternatives of Antiretroviral Therapy as Post-exposure Prophylaxis to HIV-1:FOVIR+EMTRICITABINA + LOPINAVIR/RITONAVIR VS TENOFOVIR+EMTRICITABINA + MARAVIROC (MARAVI-PEP) (clinicaltrials.gov) - Feb 20, 2013
P4, N=240, Recruiting, Sponsor: Hospital Clinic of Barcelona
N=60 --> 20 Not yet recruiting --> Recruiting
- efavirenz / Generic mfg., lopinavir/ritonavir / Generic mfg.
Enrollment closed: LIPOKAL: Clinical Trial to Assess the Effect of the Change of Efavirenz (EFV) for Lopinavir/Ritonavir (LPV/r) in Lipoatrophy in HIV-infected Patients (clinicaltrials.gov) - Feb 20, 2013
P4, N=20, Active, not recruiting, Sponsor: Juan A. Arnaiz
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting
- Trial completion: RisVac02: A Phase I Study of Modified Vaccinia Virus Ankara (MVA-B) in Healthy Volunteers at Low Risk of HIV Infection (clinicaltrials.gov) - Feb 20, 2013
P1, N=30, Completed, Sponsor: Juan A. Arnaiz
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- Trial completion: ADVANZ-3: Once-daily Antiretroviral Therapy in HIV-1 Infected Patients With CD4+ Cell Counts Below 100 Cells/Mcl (clinicaltrials.gov) - Feb 20, 2013
P4, N=108, Completed, Sponsor: Juan A. Arnaiz
Active, not recruiting --> Completed Active, not recruiting --> Completed
- Pneumovax 23 (23-valent pneumococcal polysaccharide) / Merck (MSD)
Enrollment change, Pneumococcal vaccines: Immune Responses to Pneumococcal Vaccination Among HIV-infected Subjects (clinicaltrials.gov) - Feb 19, 2013
P=N/A, N=107, Completed, Sponsor: Department of Veterans Affairs
Active, not recruiting --> Completed N=135 --> 107
- Trial initiation date: NRA RETA: Evaluation Of The Performance Of The Nitrate Reductase And Resazurin Titre Assay For The Detection of Mycobacterium Tuberculosis Complex From Sputum In A High Tb and Hiv Setting (clinicaltrials.gov) - Feb 15, 2013
P=N/A, N=600, Completed, Sponsor: Epicentre
N=135 --> 107 Initiation date: Feb 2010 --> Sep 2011
- Trial completion: NRA RETA: Evaluation Of The Performance Of The Nitrate Reductase And Resazurin Titre Assay For The Detection of Mycobacterium Tuberculosis Complex From Sputum In A High Tb and Hiv Setting (clinicaltrials.gov) - Feb 15, 2013
P=N/A, N=600, Completed, Sponsor: Epicentre
Initiation date: Feb 2010 --> Sep 2011 Active, not recruiting --> Completed
- Isentress (raltegravir) / Merck (MSD)
Clinical: Transplantation and the Use of Raltegravir in HIV-Infected Patients (clinicaltrials.gov) - Feb 13, 2013
P=N/A, N=0, Recruiting, Sponsor: Duke University
- Bydureon (exenatide XR once-weekly) / AstraZeneca
New P4 trial: Pilot Study of Bydureon to Treat Diabetes in HIV-infected Adults (clinicaltrials.gov) - Feb 13, 2013
P4, N=12, Not yet recruiting, Sponsor: Vanderbilt University
- Trial completion: Infant Male Circumcision in Gaborone, Botswana, and Surrounding Areas: Feasibility, Safety and Acceptability (clinicaltrials.gov) - Feb 13, 2013
P=N/A, N=1235, Completed, Sponsor: Brigham and Women's Hospital
Active, not recruiting --> Completed Active, not recruiting --> Completed
- Pneumovax 23 (23-valent pneumococcal polysaccharide) / Merck (MSD)
Trial completion, Pneumococcal vaccines: Immune Responses to Pneumococcal Vaccination Among HIV-infected Subjects (clinicaltrials.gov) - Feb 13, 2013
P=N/A, N=107, Completed, Sponsor: Department of Veterans Affairs
Active, not recruiting --> Completed Active, not recruiting --> Completed
- ||||| Chantix (varenicline) / Pfizer
Enrollment closed: Inter-ACTIV: Efficacy and Safety of Varenicline Among HIV-infected Patients (clinicaltrials.gov) - Feb 11, 2013
P3, N=248, Active, not recruiting, Sponsor: French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS)
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- efavirenz / Generic mfg., nevirapine / Generic mfg.
Trial completion: Genetic Determinants of the Metabolism of Non-nucleoside Reverse Transcriptase Inhibitors (clinicaltrials.gov) - Feb 11, 2013
P1, N=33, Completed, Sponsor: Vanderbilt University
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- Isentress (raltegravir) / Merck (MSD)
Trial completion: Genetic Predictors of Raltegravir Penetration Into Cerebrospinal Fluid (clinicaltrials.gov) - Feb 11, 2013
P2/3, N=40, Completed, Sponsor: Vanderbilt University
Active, not recruiting --> Completed Active, not recruiting --> Completed
- | naltrexone / Generic mfg.
Trial initiation date: WHATIF: Clinical Trial to Reduce Drinking in Women With HIV (clinicaltrials.gov) - Feb 10, 2013
P3, N=240, Recruiting, Sponsor: University of Florida
Active, not recruiting --> Completed Initiation date: Jul 2012 --> Dec 2012
- | Trial completion: Reducing HIV: Safer Sex Skill Building in Pregnant Drug Abusing Women (clinicaltrials.gov) - Feb 10, 2013
P2/3, N=380, Completed, Sponsor: Virginia Commonwealth University
Initiation date: Jul 2012 --> Dec 2012 Not yet recruiting --> Completed
- Isentress (raltegravir) / Merck (MSD)
Trial completion: Efficacy of Raltegravir in a Large Urban HIV Clinical Population in Milan (clinicaltrials.gov) - Feb 7, 2013
P=N/A, N=400, Completed, Sponsor: Universit
Not yet recruiting --> Completed Not yet recruiting --> Completed
- Trial completion, Adherence: HAART Adherence Among HIV-infected Persons and the Factors Affecting Treatment Adherence (clinicaltrials.gov) - Feb 7, 2013
P=N/A, N=150, Completed, Sponsor: University of Tartu
Not yet recruiting --> Completed Active, not recruiting --> Completed
- prednisolone / Generic mfg.
Trial completion: ProCort1: Progression of HIV-Disease Under Low Dose Corticosteroids (clinicaltrials.gov) - Feb 6, 2013
P2, N=326, Completed, Sponsor: Medical Mission Institute, Germany
Active, not recruiting --> Completed Active, not recruiting --> Completed
- || vicriviroc (MK-7690) / Merck (MSD)
Enrollment change: COVER: Registry to Assess Long-term Outcome in HIV Subjects Who Participated in Phase 2 and 3 Clinical Trials Involving Vicriviroc (Study P04999) (clinicaltrials.gov) - Feb 5, 2013
P=N/A, N=180, Completed, Sponsor: Merck Sharp & Dohme Corp.
Active, not recruiting --> Completed N=642 --> 180
- acetylcysteine solution / Generic mfg.
Trial completion: Role of HIV on Glutathione Synthesis and Oxidative Stress (clinicaltrials.gov) - Feb 4, 2013
P1, N=10, Completed, Sponsor: Baylor College of Medicine
N=642 --> 180 Recruiting --> Completed
- |||||||||| ribavirin / Generic mfg.
New P3 trial: A Phase 3, Open-label Study to Investigate the Efficacy and Safety of Sofosbuvir Plus Ribavirin in Chronic Genotype 1, 2, 3 and 4 Hepatitis C Virus (HCV) and Human Immunodeficiency Virus (HIV) Co-infected Adults (clinicaltrials.gov) - Feb 3, 2013
P3, N=270, Active, not recruiting, Sponsor: Gilead Sciences
- | darunavir/ritonavir / Generic mfg.
Enrollment change: Non-interventional Study on Use of Darunavir With Ritonavir in Clinical Practice (clinicaltrials.gov) - Jan 31, 2013
P4, N=31, Completed, Sponsor: Janssen-Cilag S.p.A.
Recruiting --> Completed N=900 --> 31
- | darunavir/ritonavir / Generic mfg.
Trial completion: Non-interventional Study on Use of Darunavir With Ritonavir in Clinical Practice (clinicaltrials.gov) - Jan 31, 2013
P4, N=31, Completed, Sponsor: Janssen-Cilag S.p.A.
N=900 --> 31 Active, not recruiting --> Completed
- Enrollment change: Autologous T-Cells Genetically Modified at the CCR5 Gene by Zinc Finger Nucleases SB-728 for HIV (clinicaltrials.gov) - Jan 30, 2013
P1, N=12, Completed, Sponsor: University of Pennsylvania
Active, not recruiting --> Completed N=18 --> 12
- Isentress (raltegravir) / Merck (MSD)
Trial completion, Metastases: LIVERAL: Pharmacokinetic Study of Raltegravir in Human Immunodeficiency Virus/Hepatitis C Virus (HIV/VHC) Coinfected Patients With Advanced (Child-Pugh C) Hepatic Cirrhosis (clinicaltrials.gov) - Jan 30, 2013
P1, N=10, Completed, Sponsor: Fundacion para la Investigacion Biomedica del Hospital Universitario Ramon y Cajal
N=18 --> 12 Active, not recruiting --> Completed
- | Trial completion: Autologous T-Cells Genetically Modified at the CCR5 Gene by Zinc Finger Nucleases SB-728 for HIV (clinicaltrials.gov) - Jan 30, 2013
P1, N=12, Completed, Sponsor: University of Pennsylvania
Active, not recruiting --> Completed Active, not recruiting --> Completed
- | ASC-09 / J&J
Trial initiation date, Monotherapy: A Study to Determine the Antiviral Activity of TMC310911 When Administered With Ritonavir in Treatment-Naive Human Immunodeficiency Virus - Type 1 (HIV-1) Infected Patients (clinicaltrials.gov) - Jan 29, 2013
P2a, N=33, Completed, Sponsor: Tibotec Pharmaceuticals, Ireland
Active, not recruiting --> Completed Initiation date: Mar 2009 --> Jun 2009
- Enrollment change: HIV Screening in the Emergency Department Setting (clinicaltrials.gov) - Jan 29, 2013
P=N/A, N=9572, Completed, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Initiation date: Mar 2009 --> Jun 2009 N=4000 --> 9572
- |||||||||| Genvoya (elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide) / Gilead, Stribild (elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate) / Gilead, Japan Tobacco
New P3 trial: Study to Evaluate the Safety and Efficacy of E/C/F/TAF (Genvoya (clinicaltrials.gov) - Jan 29, 2013
P3, N=840, Active, not recruiting, Sponsor: Gilead Sciences
- Trial completion: HIV Screening in the Emergency Department Setting (clinicaltrials.gov) - Jan 29, 2013
P=N/A, N=9572, Completed, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
N=4000 --> 9572 Recruiting --> Completed
- Selzentry (maraviroc) / ViiV Healthcare
Trial completion: Maraviroc in Immunological Non-Responder (INR) HIV-1-infected Subjects (clinicaltrials.gov) - Jan 28, 2013
P4, N=100, Completed, Sponsor: Ospedale L. Sacco
Recruiting --> Completed Active, not recruiting --> Completed
- ||| HSV vaccine (GEN-003) / Genocea, Shionogi
Enrollment closed: Safety and Immunogenicity Study of Therapeutic HSV-2 Vaccine (clinicaltrials.gov) - Jan 27, 2013
P1/2, N=150, Active, not recruiting, Sponsor: Genocea Biosciences, Inc.
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- ||||| Selzentry (maraviroc) / ViiV Healthcare
New P4 trial: An Expanded Access Protocol for Subjects Who Have Completed Clinical Studies Involving Maraviroc (clinicaltrials.gov) - Jan 24, 2013
P4, N=124, Active, not recruiting, Sponsor: ViiV Healthcare
- ||| Isentress (raltegravir) / Merck (MSD)
Trial completion, Combination therapy: RACING: Management of Human Immunodeficiency Virus 1 (HIV-1) Participants Treated With Antiretroviral (ARV) Combination Therapy Including Raltegravir (MK-0518-138) (clinicaltrials.gov) - Jan 23, 2013
P=N/A, N=482, Completed, Sponsor: Merck Sharp & Dohme Corp.
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- Selzentry (maraviroc) / ViiV Healthcare
Trial completion: Switching the Non-nucleoside Reverse Transcriptase Inhibitor (NNRTI) or Protease Inhibitor (PI) to Maraviroc in HIV Subjects (clinicaltrials.gov) - Jan 22, 2013
P4, N=30, Completed, Sponsor: Germans Trias i Pujol Hospital
Active, not recruiting --> Completed Active, not recruiting --> Completed
- | trimethoprim/sulfamethoxazole / Generic mfg., mefloquine / Generic mfg.
Trial completion: PACOME: Prevention of Pregnancy-associated Malaria in HIV-infected Women: Cotrimoxazole Prophylaxis Versus Mefloquine (clinicaltrials.gov) - Jan 20, 2013
P3, N=430, Completed, Sponsor: Institut de Recherche pour le Developpement
Active, not recruiting --> Completed Active, not recruiting --> Completed
- | emtricitabine/tenofovir disoproxil fumarate / Generic mfg.
New P2 trial: An Open Label Demonstration Project and Phase II Safety Study of Pre-Exposure Prophylaxis (clinicaltrials.gov) - Jan 17, 2013
P2, N=200, Active, not recruiting, Sponsor: Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
- Enrollment closed: CCRC: A Project of the Treatment of HIV Enteropathy With ImmunoLin (clinicaltrials.gov) - Jan 17, 2013
P=N/A, N=12, Active, not recruiting, Sponsor: University of California, Davis
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- | DermaVir Patch (HIV DNA vaccine topical) / Genetic Immunity
Trial completion: Antiretroviral-Sparing Concept With HIV-specific T Cell Precursors With High Proliferative Capacity (PHPC) (clinicaltrials.gov) - Jan 16, 2013
P2, N=16, Completed, Sponsor: Genetic Immunity
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- efavirenz / Generic mfg., lopinavir/ritonavir / Generic mfg.
Trial termination, Metastases: Immune Reconstitution of Lopinavir/Ritonavir-Based vs Efavirenz-based HAART in Advanced HIV Disease (clinicaltrials.gov) - Jan 15, 2013
P4, N=15, Terminated, Sponsor: Rush University Medical Center
Recruiting --> Terminated; Study stopped 12/2010 due to poor enrollment. Only 15 of 60 needed enrolled.
- efavirenz / Generic mfg., lopinavir/ritonavir / Generic mfg.
Enrollment change, Metastases: Immune Reconstitution of Lopinavir/Ritonavir-Based vs Efavirenz-based HAART in Advanced HIV Disease (clinicaltrials.gov) - Jan 15, 2013
P4, N=15, Terminated, Sponsor: Rush University Medical Center
Only 15 of 60 needed enrolled. N=60 --> 15
- | emtricitabine/tenofovir disoproxil fumarate / Generic mfg.
New P2 trial: An Open Label Demonstration Project and Phase II Safety Study of Pre-Exposure Prophylaxis Use Among 15 to 17 Year Old Young Men Who Have Sex With Men (YMSM) (clinicaltrials.gov) - Jan 14, 2013
P2, N=100, Recruiting, Sponsor: Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
- nevirapine / Generic mfg., artemether/lumefantrine / Generic mfg.
Trial completion: Interactions Between Artemether-lumefantrine and Antiretrovirals in HIV-patients With Uncomplicated Malaria in Tanzania (clinicaltrials.gov) - Jan 14, 2013
P4, N=830, Completed, Sponsor: University of Copenhagen
N=60 --> 15 Recruiting --> Completed
- methadone / Generic mfg.
Trial completion: HIV and Hepatitis Care Coordination in Methadone Treatment (clinicaltrials.gov) - Jan 14, 2013
P=N/A, N=489, Completed, Sponsor: University of California, San Francisco
Recruiting --> Completed Recruiting --> Completed
- leucovorin calcium / Generic mfg.
Clinical: Folinic Acid and Vascular Reactivity in HIV (clinicaltrials.gov) - Jan 13, 2013
P=N/A, N=30, Completed, Sponsor: Hospital de Clinicas de Porto Alegre
- Trial completion: Immunogenicity and Safety Trial of the HIV-1 Tat Vaccine (clinicaltrials.gov) - Jan 13, 2013
P2, N=168, Completed, Sponsor: Istituto Superiore di Sanita
Recruiting --> Completed Active, not recruiting --> Completed
- || Enrollment change: Typing of Human Papilloma Virus (HPV) From Female Genital Warts (clinicaltrials.gov) - Jan 12, 2013
P=N/A, N=156, Completed, Sponsor: University of Cape Town
Active, not recruiting --> Completed N=130 --> 156